AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A foam comprising a liquid phase and a gas phase wherein

the liquid phase comprises at least one sclerosing agent and ~~is at least 20% vol/vol of~~ at least one viscosity enhancing agent, the liquid phase having a viscosity between 2cP and 5cP; and

the gas phase comprises at least ~~50%~~ 90% CO2;

and wherein the foam has a density less than 0.25 g/ml and half life of greater than ~~100~~ 90 secs.

2-3. (Canceled)

4. (Previously presented) A foam of claim 1, wherein the gas phase comprises at least 99% CO2.

5. (Previously presented) A foam of claim 1, wherein the gas phase consists essentially of CO2.

6-7. (Canceled)

8. (Currently amended) A foam of claim 1, wherein the half life is at least ~~180~~ 100 seconds.

9. (Currently amended) A foam of claim 1, wherein the density ranges from ~~0.07 to 0.22~~ 0.07-0.19 g/ml.

10-11. (Canceled)

12. (Currently amended) A foam of claim 1, wherein the density ranges from ~~0.08 to 0.14~~ 0.07-0.16 g/ml.

13-15. (Canceled)

16. (Previously presented) A foam of claim 1, wherein the at least one viscosity enhancing agent is chosen from glycerol and PVP.

17. (Canceled)

18. (Currently amended) A foam of claim 1, wherein the at least one sclerosing agent is chosen from polidocanol~~, glycerol~~ and sodium tetradecyl sulphate.

19. (Previously presented) A foam of claim 1, wherein the at least one sclerosing agent is polidocanol.

20. (Currently amended) A foam of claim ~~1~~ 19, wherein the polidocanol is present in a concentration ranging from 0.5 to 4% vol/vol in the liquid phase.

21-24. (Canceled)

25. (Previously presented) A foam of claim 1, wherein at least 50% by number of the gas bubbles of at least 25μm diameter are of no more than 120μm diameter and at least 95% of these gas bubbles are of no more than 250μm diameter.

26. (Canceled)

27. (Previously presented) A method for phlebologic treatment comprising injecting a foam of claim 1 into vessels to be treated.

28. (Previously presented) The method of claim 27 wherein substantially the entire greater saphenous vein of one leg of a human patient is treated by a single injection of foam.

29. (Previously presented) The method of claim 27 wherein the single injection uses an amount ranging from 10ml to 50ml of foam.

30. (Canceled)

31. (Previously presented) The method of claim 27 wherein the single injection uses an amount ranging from 15ml to 30ml of foam.

32-63. (Canceled)

64. (Currently amended) A method for producing a foam comprising

passing a mixture comprising at least one physiologically acceptable blood dispersible gas, the gas being at least 90% carbon dioxide, and at least one aqueous sclerosant liquid, the liquid comprising at least one sclerosing agent and at least one viscosity enhancing agent and having a viscosity between 2cP and 5cP, through one or more passages having at least one cross-sectional dimension of from 0.1 to 15 μm, and ~~the mixture comprises not more than 0.8% nitrogen gas by volume,~~

the ratio of gas to liquid being controlled such that the foam is produced having a density less than 0.25 g/cm and a half-life of greater than ~~100~~ 90 secs.

65-86. (Canceled)

87. (New) The foam of claim 1, wherein the foam has a half life of greater than 120 secs.

88. (New) The method of claim 27 wherein the single injection uses an amount ranging from 10ml to 40ml of foam.